Evidence map›Paper›PMID 32803133›Full record

ReviewHemaSphere2020

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.

Dipti Talaulikar, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Maria J Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in HemaSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Dipti TalaulikarDepartment of Hematology, Canberra Hospital and College of Health and Medicine, Australian National University, Canberra, Australia.
Ranjana H AdvaniDepartment of Medicine, Stanford University Medical Center, Stanford, California, USA.
Andrew R BranaganDivision of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Christian BuskeComprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
Meletios A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Shirley D'SaWaldenström Clinic, Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.
Maria J KerstenDepartment of Hematology, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), University of Amsterdam, Amsterdam, The Netherlands.
Veronique LeblondService of Clinical Hematology, Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris, France.
Monique C MinnemaDepartment of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
Roger G OwenHaematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
Maria Lia PalombaLymphoma Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.
Alessandra TedeschiDepartment of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Judith TrotmanDepartment of Haematology, Concord Hospital, Department of Medicine, University of Sydney, Sydney, Australia.
Marzia VarettoniFondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Josephine M VosDepartment of Hematology and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
Steven P TreonBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Jorge J CastilloBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.

Identifiers

PMID32803133
PMCPMC7410025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.